The Response of Mitochondrial Respiration and Quantity in Skeletal Muscle and Adipose Tissue to Exercise in Humans with Prediabetes.
adipose tissue
exercise
fat
mitochondria
muscle
obesity
prediabetes
type 2 diabetes
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
received:
17
09
2021
revised:
28
10
2021
accepted:
03
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes, but its contribution to the early stages of dysglycemia remains poorly understood. By collecting a high-resolution stage-based spectrum of dysglycemia, our study fills this gap by evaluating derangement in both the function and quantity of mitochondria. We sampled mitochondria in skeletal muscle and subcutaneous adipose tissues of subjects with progressive advancement of dysglycemia under a three-month exercise intervention. We measured clinical metabolic parameters and gathered skeletal muscle and adipose tissue biopsies before and after the three-month exercise intervention. We then assayed the number of mitochondria via citrate synthase (CS) activity and functional parameters with high-resolution respirometry. In muscle, there were no differences in mitochondrial quantity or function at baseline between normoglycemics and prediabetics. However, the intervention caused improvement in CS activity, implying an increase in mitochondrial quantity. By contrast in adipose tissue, baseline differences in CS activity were present, with the lowest CS activity coincident with impaired fasting glucose and impaired glucose tolerance (IFG + IGT). Finally, CS activity, but few of the functional metrics, improved under the intervention. We show that in prediabetes, no differences in the function or amount of mitochondria (measured by CS activity) in skeletal muscle are apparent, but in adipose tissue of subjects with IFG + IGT, a significantly reduced activity of CS was observed. Finally, metabolic improvements under the exercise correlate to improvements in the amount, rather than function, of mitochondria in both tissues.
Sections du résumé
BACKGROUND
Mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes, but its contribution to the early stages of dysglycemia remains poorly understood. By collecting a high-resolution stage-based spectrum of dysglycemia, our study fills this gap by evaluating derangement in both the function and quantity of mitochondria. We sampled mitochondria in skeletal muscle and subcutaneous adipose tissues of subjects with progressive advancement of dysglycemia under a three-month exercise intervention.
METHODS
We measured clinical metabolic parameters and gathered skeletal muscle and adipose tissue biopsies before and after the three-month exercise intervention. We then assayed the number of mitochondria via citrate synthase (CS) activity and functional parameters with high-resolution respirometry.
RESULTS
In muscle, there were no differences in mitochondrial quantity or function at baseline between normoglycemics and prediabetics. However, the intervention caused improvement in CS activity, implying an increase in mitochondrial quantity. By contrast in adipose tissue, baseline differences in CS activity were present, with the lowest CS activity coincident with impaired fasting glucose and impaired glucose tolerance (IFG + IGT). Finally, CS activity, but few of the functional metrics, improved under the intervention.
CONCLUSIONS
We show that in prediabetes, no differences in the function or amount of mitochondria (measured by CS activity) in skeletal muscle are apparent, but in adipose tissue of subjects with IFG + IGT, a significantly reduced activity of CS was observed. Finally, metabolic improvements under the exercise correlate to improvements in the amount, rather than function, of mitochondria in both tissues.
Identifiants
pubmed: 34831236
pii: cells10113013
doi: 10.3390/cells10113013
pmc: PMC8616473
pii:
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Leading National Research Center KNOW
ID : 56/KNOW/15
Références
Diabetes. 2007 Jun;56(6):1592-9
pubmed: 17351150
Diabetes. 2004 Jun;53(6):1549-55
pubmed: 15161760
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Diabetes. 2010 Mar;59(3):572-9
pubmed: 20028948
J Proteomics. 2011 May 16;74(6):774-95
pubmed: 21414428
Endocr Rev. 2010 Jun;31(3):364-95
pubmed: 20156986
J Appl Physiol (1985). 1985 Aug;59(2):320-7
pubmed: 4030584
U S Armed Forces Med J. 1959 Jun;10(6):675-88
pubmed: 13659732
Health Technol Assess. 2012 Aug;16(33):1-236, iii-iv
pubmed: 22935084
J Physiol. 2012 Jul 15;590(14):3349-60
pubmed: 22586215
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
J Appl Physiol (1985). 2013 Feb;114(3):344-50
pubmed: 23221957
J Vis Exp. 2014 Sep 10;(91):51812
pubmed: 25285722
Diabetes. 2002 Oct;51(10):2944-50
pubmed: 12351431
Eur J Appl Physiol. 2010 May;109(2):307-16
pubmed: 20084391
Diabetes. 2006 May;55(5):1430-5
pubmed: 16644701
Ann Intern Med. 2007 Sep 18;147(6):357-69
pubmed: 17876019
Diabetologia. 2020 Aug;63(8):1491-1499
pubmed: 32529411
Diabetes. 2008 Nov;57(11):2943-9
pubmed: 18678616
Nutr Metab (Lond). 2017 Mar 2;14:24
pubmed: 28270856
Arch Intern Med. 2012 Sep 24;172(17):1306-12
pubmed: 22868691
Diabetologia. 2009 Jul;52(7):1400-8
pubmed: 19396425
Front Physiol. 2018 Dec 11;9:1781
pubmed: 30618796
J Appl Physiol (1985). 1997 Jul;83(1):166-71
pubmed: 9216960
Acta Physiol (Oxf). 2018 Jan;222(1):
pubmed: 28580772
Diabetologia. 2010 Aug;53(8):1714-21
pubmed: 20422397
Scand J Med Sci Sports. 2015 Feb;25(1):e59-69
pubmed: 24845952
Diabetes Care. 2003 Nov;26(11):2977-82
pubmed: 14578226
Diabetologia. 2011 Jun;54(6):1427-36
pubmed: 21424396
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7996-8001
pubmed: 12808136
Cell Metab. 2008 Jan;7(1):45-56
pubmed: 18177724
Cell Metab. 2017 May 2;25(5):1027-1036
pubmed: 28467922
J Clin Endocrinol Metab. 2011 Feb;96(2):494-503
pubmed: 21106709
Science. 2003 May 16;300(5622):1140-2
pubmed: 12750520
Diabetologia. 2008 May;51(5):853-61
pubmed: 18317726
J Physiol. 2017 Jun 1;595(11):3377-3387
pubmed: 28133739
J Physiol. 2000 Oct 15;528 Pt 2:379-88
pubmed: 11034627
Diabetes. 2005 Jan;54(1):8-14
pubmed: 15616005
Diabetes. 2007 Mar;56(3):720-7
pubmed: 17327442
Diabetologia. 2007 Apr;50(4):790-6
pubmed: 17334651
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
J Clin Endocrinol Metab. 2012 Sep;97(9):3261-9
pubmed: 22802091
Ann Intern Med. 2015 Sep 15;163(6):437-51
pubmed: 26167912
Diabetes Care. 2007 Mar;30(3):753-9
pubmed: 17327355
FASEB J. 2016 Oct;30(10):3413-3423
pubmed: 27402675
J Clin Endocrinol Metab. 2010 Jun;95(6):2948-56
pubmed: 20382691
N Engl J Med. 2004 Feb 12;350(7):664-71
pubmed: 14960743
FASEB J. 2016 Feb;30(2):959-70
pubmed: 26572168
Diabetes. 2014 Aug;63(8):2800-11
pubmed: 24622799
Sports Med. 2018 Aug;48(8):1809-1828
pubmed: 29934848
J Physiol. 2015 Oct 15;593(20):4677-88
pubmed: 26282186
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Diabetes. 2017 Jan;66(1):170-176
pubmed: 27737951
J Physiol. 2010 Jun 15;588(Pt 12):2023-32
pubmed: 20421291
Diabetes. 2004 Feb;53(2):294-305
pubmed: 14747278
J Vis Exp. 2017 Sep 30;(127):
pubmed: 28994752
Diabetologia. 2007 Jan;50(1):113-20
pubmed: 17093944
Horm Metab Res. 2017 Jan;49(1):50-57
pubmed: 28103623
PLoS Med. 2007 May;4(5):e154
pubmed: 17472434
Diabetes Care. 2009 Nov;32 Suppl 2:S194-8
pubmed: 19875551
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Obesity (Silver Spring). 2015 Oct;23(10):2022-9
pubmed: 26337597
Diabetologia. 2010 Sep;53(9):1976-85
pubmed: 20526759
Cochrane Database Syst Rev. 2017 Dec 04;12:CD003054
pubmed: 29205264
Am J Physiol Regul Integr Comp Physiol. 2008 Jul;295(1):R264-72
pubmed: 18417645
Diabetes Care. 2006 Aug;29(8):1909-14
pubmed: 16873801
J Obes Metab Syndr. 2018 Sep 30;27(3):150-157
pubmed: 31089557
Methods Mol Biol. 2012;810:25-58
pubmed: 22057559